Enron Mail

From: brown_mary_jo@lilly.com To: Subject: ***PRESS RELEASE*** In a New Phase III Study, CialisTM (IC351) 20 Cc: Bcc: Date: Fri, 1 Jun 2001 13:31:49 -0700 (PDT) Regardless of Severity Cc: brown_mary_jo@lilly.com Mime-Version: 1.0 Content-Type: text/plain; charset=us-ascii Content-Transfer-Encoding: 7bit Bcc: brown_mary_jo@lilly.com X-From: BROWN_MARY_JO@LILLY.COM@ENRON <IMCEANOTES-BROWN+5FMARY+5FJO+40LILLY+2ECOM+40ENRON@ENRON.com< X-To: alfred.gilman@email.swmed.edu, george.fisher@kodak.com, jterzuoli@ibjwhitehall.com, karen.n.horn@marsh.com, Lay, Kenneth </O=ENRON/OU=NA/CN=RECIPIENTS/CN=KLAY<, kseifert@kcc.com, prendergast@mayo.edu, scb@purdue.edu, win.bischoff@ssmb.com X-cc: BROWN_MARY_JO@LILLY.COM X-bcc: X-Folder: \Lay, Kenneth\Lay, Kenneth\Inbox X-Origin: LAY-K X-FileName: Lay, Kenneth.pst The attached press release was issued over Business Wire this morning at 7:55 AM ET. - Cialis Phase III Duration FINAL 060101.doc